戻る Agenda
[V2-S1] Changes Required for Risk Minimization Materials
Session Chair(s)
Mamoru Narukawa, PHD, RPH
Professor, Kitasato University, Japan
It has been 5 years since the RMP was implemented in Japan. The risk minimization measure, which is vital in considering the RMP as well as the Benefit Risk balance, is becoming more important. With regard to materials for healthcare professionals and for patients which have been part of the risk minimization measure in Japan, this session will discuss the direction of changes required in the future, based on current issues.
Speaker(s)
Kazuhiko Ishida, MSC, RPH
Director, Pharmacovigilance, Astellas Pharma Inc., Japan
Points to Consider for Implementation of Risk Minimization Materials
Masahiro Hayashi, PHD
Pharmaceutical affairs specialist, Department of Pharmacy, Toranomon Hospital, Japan
Recognition and Expectation of Hospital Pharmacists on Risk Minimization Materials
Asami Ezaki, PHD
Division Director, PR Section, Office of Planning and Operations, Pharmaceuticals and Medeical Devices Agency (PMDA), Japan
Current Status and Future of Information Providing Materials for Risk Minimization